A CB1 cannabinoid receptor blocker showed antidepressant-like effects in stressed mice, and these effects were mediated through the opioid system, revealing a connection between cannabinoid and opioid pathways in depression.
Read this if you are interested in how the cannabinoid and opioid systems interact in mood regulation.
Low-dose opioid blocker enhanced the antidepressant effect of CB1 blockade by 5-fold (0.5 mg/kg reduced to 0.1 mg/kg).
What the researchers found
Mice subjected to foot-shock stress showed increased immobility in standard depression tests (forced swimming test and tail suspension test), modeling depressive behavior. The CB1 receptor inverse agonist AM-251 reversed this stress-induced depression-like behavior.
The key finding was that the opioid system appears to mediate this antidepressant effect. When researchers gave a low dose of the opioid blocker naltrexone alongside AM-251, the antidepressant effect was enhanced, meaning less AM-251 was needed. Conversely, a low dose of morphine blocked AM-251's antidepressant effect entirely.
None of the drug combinations affected general locomotor activity, confirming the effects were specific to depression-like behavior rather than general changes in movement.
Why it matters
This study reveals a previously unknown interaction between the cannabinoid and opioid systems in stress-related depression. The finding that blocking CB1 receptors produces antidepressant effects through opioid signaling suggests these two major neurotransmitter systems are more interconnected in mood regulation than previously recognized.
The numbers in context
AM-251 at 0.5 mg/kg reversed stress-induced immobility. Co-administration with sub-effective naltrexone reduced the effective AM-251 dose to 0.1 mg/kg. Sub-effective morphine completely blocked AM-251's antidepressant effect at 0.5 mg/kg.
How the study worked
Male mice were subjected to intermittent foot-shock stress for 30 minutes, then tested in the forced swimming test and tail suspension test. Researchers tested AM-251 alone and in combination with naltrexone (opioid antagonist) or morphine (opioid agonist). Locomotor activity was measured separately to rule out general motor effects.
What this study cannot tell us
This was a mouse study using acute stress and acute drug treatment. Depression in humans is a chronic condition with complex causes that cannot be fully captured by rodent tests. AM-251 is a research tool compound, not a clinical drug. The results may not translate directly to human depression.
How to read the evidence
Preliminary evidence from an animal study. The mechanistic interaction is clearly demonstrated in mice but has not been tested in human depression.
When this study was published
Published in 2016. The cannabinoid-opioid interaction in mood disorders remains an active area of preclinical research.
The bigger picture
Both the endocannabinoid and opioid systems are involved in mood regulation, pain processing, and reward. This study provides a mechanistic link between them in the context of stress-induced depression, which could inform development of novel treatments targeting both systems.
Questions still open
- Would this cannabinoid-opioid interaction hold in chronic depression models? Could low-dose opioid antagonists enhance the mood effects of cannabinoid modulation in humans? Does endocannabinoid tone influence the antidepressant effects of opioid-targeted medications?
Common questions
Does blocking cannabinoid receptors treat depression?
How are the cannabinoid and opioid systems connected?
Read the original research
Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice.
Clinical and experimental pharmacology & physiology, 43(2), 203-12
Citation
Ostadhadi, Sattar; Haj-Mirzaian, Arya; Nikoui, Vahid; Kordjazy, Nastaran; Dehpour, Ahmad-Reza. (2016). Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice.. Clinical and experimental pharmacology & physiology, 43(2), 203-12. https://doi.org/10.1111/1440-1681.12518
Explore the wider topic
- LGBTQ+ and Cannabis: Higher Use Rates and Recovery
- Cannabis-Induced Psychosis: What It Is, Who's at Risk, and What to Do
- BetterHelp, Cerebral, and Online Therapy: Honest Review
- Quitting Weed with ADHD: Why It Is Harder and What Actually Helps
- Quitting Weed with Depression: What You Need to Know
- Quitting Weed with PTSD: A Practical Guide
- Self-Medicating with Weed: Why It Works Until It Doesn't
- Weed and OCD: Self-Medicating Intrusive Thoughts
- Weed and PTSD: What the Research Actually Shows
- Weed and Childhood Trauma: ACEs, Self-Medication, and the Path to Real Healing
- Weed and Suicidal Thoughts: What You Need to Know